Cargando…

Novel and Potent Dopamine D(2) Receptor Go-Protein Biased Agonists

[Image: see text] The discovery of functionally biased and physiologically beneficial ligands directed toward G-protein coupled receptors (GPCRs) has provided the impetus to design dopamine D(2) receptor (D(2)R) targeted molecules that may be therapeutically advantageous for the treatment of certain...

Descripción completa

Detalles Bibliográficos
Autores principales: Bonifazi, Alessandro, Yano, Hideaki, Guerrero, Adrian M., Kumar, Vivek, Hoffman, Alexander F., Lupica, Carl R., Shi, Lei, Newman, Amy Hauck
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Chemical Society 2019
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6371206/
https://www.ncbi.nlm.nih.gov/pubmed/30775693
http://dx.doi.org/10.1021/acsptsci.8b00060
Descripción
Sumario:[Image: see text] The discovery of functionally biased and physiologically beneficial ligands directed toward G-protein coupled receptors (GPCRs) has provided the impetus to design dopamine D(2) receptor (D(2)R) targeted molecules that may be therapeutically advantageous for the treatment of certain neuropsychiatric or basal ganglia related disorders. Here we describe the synthesis of a novel series of D(2)R agonists linking the D(2)R unbiased agonist sumanirole with privileged secondary molecular fragments. The resulting ligands demonstrate improved D(2)R affinity and selectivity over sumanirole. Extensive in vitro functional studies and bias factor analysis led to the identification of a novel class of highly potent Go-protein biased full D(2)R agonists with more than 10-fold and 1000-fold bias selectivity toward activation of specific G-protein subtypes and β-arrestin, respectively. Intracellular electrophysiological recordings from midbrain dopamine neurons demonstrated that Go-protein selective agonists can elicit prolonged ligand-induced GIRK activity via D(2)Rs, which may be beneficial in the treatment of dyskinesias associated with dopamine system dysfunction.